MK-8527
Phase 3Small molecule
Merck & Co.MK-8527 is one of 86 small molecule programs targeting HIV-1 infection. It is currently in Phase 3.
3
Indications
15
Total Trials
5
Active Trials
85
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
296 competitors in Immunodeficiency
#DrugCompanyPhaseTrials
1Cabenuva
GSKPhase 3
Viread
GileadPhase 3
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Retrovir
BBp Consulting, Inc
Phase 3
Prezista
WWim Janssens
Phase 3
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Igpro20
CSL BehringPhase 3
GAMUNEX-C
Grifols Therapeutics LLCPhase 3
PPSV23
Merck & Co.Phase 3
V116
Merck & Co.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Adult3 trials
Human Immunodeficiency Virus (HIV)3 trials
Moderate Hepatic Impairment1 trial
HIV-1 infection1 trial
6 more indications
Renal Impairment1 trial
Interaction1 trial
Tenofovir Disoproxil Fumarate1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for MK-8527. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company